JP2016518124A - 抗がん療法に対する腫瘍細胞応答マーカー - Google Patents

抗がん療法に対する腫瘍細胞応答マーカー Download PDF

Info

Publication number
JP2016518124A
JP2016518124A JP2016509033A JP2016509033A JP2016518124A JP 2016518124 A JP2016518124 A JP 2016518124A JP 2016509033 A JP2016509033 A JP 2016509033A JP 2016509033 A JP2016509033 A JP 2016509033A JP 2016518124 A JP2016518124 A JP 2016518124A
Authority
JP
Japan
Prior art keywords
mir
tumor
cancer
drug
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016509033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518124A5 (enExample
Inventor
デイビッド フレンドウェイ，
デイビッド フレンドウェイ，
グスターボ ドロゲット，
グスターボ ドロゲット，
マシュー コス，
マシュー コス，
ギャビン サーストン，
ギャビン サーストン，
ジョージ ディー． ヤンコポーロス，
ジョージ ディー． ヤンコポーロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2016518124A publication Critical patent/JP2016518124A/ja
Publication of JP2016518124A5 publication Critical patent/JP2016518124A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016509033A 2013-04-15 2014-04-15 抗がん療法に対する腫瘍細胞応答マーカー Ceased JP2016518124A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812033P 2013-04-15 2013-04-15
US61/812,033 2013-04-15
PCT/US2014/034217 WO2014172376A2 (en) 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2016518124A true JP2016518124A (ja) 2016-06-23
JP2016518124A5 JP2016518124A5 (enExample) 2017-06-01

Family

ID=51686961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509033A Ceased JP2016518124A (ja) 2013-04-15 2014-04-15 抗がん療法に対する腫瘍細胞応答マーカー

Country Status (14)

Country Link
US (2) US10023916B2 (enExample)
EP (1) EP2986739B1 (enExample)
JP (1) JP2016518124A (enExample)
KR (1) KR20150140728A (enExample)
CN (1) CN105308189B (enExample)
AU (1) AU2014254091B2 (enExample)
BR (1) BR112015026095A8 (enExample)
CA (1) CA2909642A1 (enExample)
MX (1) MX2015014486A (enExample)
MY (1) MY180365A (enExample)
RU (1) RU2664180C2 (enExample)
SG (2) SG11201508058TA (enExample)
WO (1) WO2014172376A2 (enExample)
ZA (1) ZA201507309B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091386A1 (ko) * 2018-10-30 2020-05-07 가톨릭대학교산학협력단 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도
KR20210085690A (ko) * 2019-12-31 2021-07-08 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510569B2 (en) 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
US10023916B2 (en) 2013-04-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
CN104388561A (zh) * 2014-11-14 2015-03-04 浙江理工大学 肝癌生物标记物及其用途
CN106636315B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒
CN106636311B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 大肠癌相关microRNA检测试剂盒
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
CN105950768A (zh) * 2016-07-01 2016-09-21 江苏医诺万细胞诊疗有限公司 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法
CN106350582B (zh) * 2016-08-25 2020-02-14 朱伟 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
CN107913284B (zh) * 2016-10-09 2022-09-16 上海市东方医院 miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用
CN106778073B (zh) * 2017-01-19 2019-09-06 北京吉因加科技有限公司 一种评估肿瘤负荷变化的方法和系统
CN106834470A (zh) * 2017-02-17 2017-06-13 张灏 miRNA在制备癌症诊断试剂盒中的用途
CN106676196B (zh) * 2017-03-10 2019-05-07 上海核盾生物科技有限公司 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒
CN107326092B (zh) * 2017-08-25 2021-07-20 深圳市恩普电子技术有限公司 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用
CN108220381A (zh) * 2017-12-07 2018-06-29 国家卫生计生委科学技术研究所 试剂在制备药物中的用途以及筛选药物的方法
CN108531586B (zh) * 2018-03-19 2022-03-29 朱伟 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用
CN109097473A (zh) * 2018-08-24 2018-12-28 南京求臻基因科技有限公司 一种非小细胞肺癌辅助诊断试剂盒
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CN109593852B (zh) * 2018-12-24 2022-03-08 朱伟 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用
EP3969053A4 (en) * 2019-05-15 2023-01-11 The University of Chicago LACTATE RESPONSE SYSTEM AND METHODS
CN110484620B (zh) * 2019-08-09 2023-09-19 深圳市第二人民医院 生物标志物及其在制备诊断ptmc的产品中的应用
WO2021108043A1 (en) 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
CN113930505B (zh) * 2020-03-30 2022-04-19 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒及装置
CN111808950B (zh) * 2020-06-02 2023-11-14 中南大学湘雅医院 一种甲状腺乳头状癌miRNA标志物及其应用
CA3185666A1 (en) * 2020-06-19 2021-12-23 Agensys, Inc. Markers for use in methods for treating cancers with antibody drug conjugates (adc)
CN111676291B (zh) * 2020-07-14 2021-04-13 徐州医科大学 一种用于肺癌患病风险评估的miRNA标志物
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
CN114150063B (zh) * 2021-12-09 2024-12-17 觅瑞（杭州）生物科技有限公司 膀胱癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
WO2024006581A1 (en) * 2022-07-01 2024-01-04 City Of Hope Biomarkers in colorectal cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503480A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド 腫瘍の治療
JP2009543552A (ja) * 2006-07-13 2009-12-10 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 結腸癌関連疾患の診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548394A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
ES2343204T3 (es) 2005-09-20 2010-07-26 Scinopharm Singapore Pte, Ltd. Formas cristalinas nuevas de hidrocloruro de irinotecan.
US20100004253A1 (en) * 2006-09-19 2010-01-07 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008143795A1 (en) 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
ES2600165T3 (es) * 2008-02-28 2017-02-07 The Ohio State University Research Foundation Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis
EP2334805A1 (en) * 2008-06-04 2011-06-22 Andor Pivarcsi Skin cancer associated micrornas
JP2012509675A (ja) 2008-11-25 2012-04-26 ジェン−プロウブ インコーポレイテッド 低分子ｒｎａを検出するための組成物および方法、ならびにその使用
US20120231970A1 (en) 2009-09-30 2012-09-13 Japan Health Sciences Foundation Colon cancer marker and method for testing for colon cancer
WO2011156777A1 (en) 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
US20120264131A1 (en) 2011-03-18 2012-10-18 Baylor Research Institute CHANGES IN THE EXPRESSION OF miR-200c/141 CLUSTER OF microRNAs AS BIOMARKERS FOR EPITHELIAL-TO-MESENCHYMAL TRANSITION IN HUMAN COLORECTAL CANCER METASTASIS
WO2012170711A1 (en) 2011-06-07 2012-12-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L Circulating biomarkers for cancer
WO2012174293A2 (en) 2011-06-14 2012-12-20 Nestec Sa Methods for identifying inflammatory bowel disease patients with dysplasia or cancer
WO2014078850A1 (en) * 2012-11-19 2014-05-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery
US10023916B2 (en) 2013-04-15 2018-07-17 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503480A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド 腫瘍の治療
JP2009543552A (ja) * 2006-07-13 2009-12-10 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 結腸癌関連疾患の診断及び治療のためのマイクロｒｎａに基づいた方法及び組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. CANCER, vol. 70, no. 3, JPN6018048305, 1997, pages 335 - 340, ISSN: 0003935090 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091386A1 (ko) * 2018-10-30 2020-05-07 가톨릭대학교산학협력단 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도
KR20210085690A (ko) * 2019-12-31 2021-07-08 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
KR102293777B1 (ko) 2019-12-31 2021-08-25 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법

Also Published As

Publication number Publication date
US20140308370A1 (en) 2014-10-16
WO2014172376A3 (en) 2015-10-29
MX2015014486A (es) 2016-07-21
AU2014254091A1 (en) 2015-11-12
ZA201507309B (en) 2017-08-30
AU2014254091B2 (en) 2019-03-21
BR112015026095A8 (pt) 2020-01-21
RU2015148638A (ru) 2017-05-22
SG11201508058TA (en) 2015-10-29
US10023916B2 (en) 2018-07-17
KR20150140728A (ko) 2015-12-16
EP2986739A2 (en) 2016-02-24
SG10201708464TA (en) 2017-11-29
CN105308189B (zh) 2018-09-04
CA2909642A1 (en) 2014-10-23
US20180291468A1 (en) 2018-10-11
CN105308189A (zh) 2016-02-03
BR112015026095A2 (pt) 2017-07-25
EP2986739B1 (en) 2018-04-04
EP2986739A4 (en) 2017-03-01
MY180365A (en) 2020-11-28
RU2664180C2 (ru) 2018-08-15
HK1214630A1 (en) 2016-07-29
WO2014172376A2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
AU2014254091B2 (en) Markers of tumor cell response to anti-cancer therapy
JP5976726B2 (ja) 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
EP3520775A1 (en) Methods for treating cancer and predicting drug responsiveness in cancer patients
US10900089B2 (en) Methods for predicting drug responsiveness in cancer patients
JP2016025853A (ja) 固形癌の診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
MX2014004810A (es) Microarn plasmaticos para la deteccion de cancer colorrectal temprano.
EP3122905B1 (en) Circulating micrornas as biomarkers for endometriosis
CN103492566A (zh) 乳癌患者对曲妥珠单抗的治疗敏感性预测用组合物和方法
CA3032827A1 (en) Methods for diagnosing and treating esophageal cancer
US20140329714A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
Ravichandran et al. An updated review on molecular biomarkers in diagnosis and therapy of colorectal cancer
EP2942399B1 (en) Method for the diagnosis of breast cancer
HK1214630B (en) Markers of tumor cell response to anti-cancer therapy
JP2020502263A (ja) Ｎｓｃｌｃを有する患者の処置のための薬剤及び応答を予測するための方法
WO2025014933A1 (en) Targeting tim-3 in mapk-driven glioma
HK40049419A (en) Circulating micrornas as biomarkers for endometriosis
HK40006425A (en) Methods for treating cancer and predicting drug responsiveness in cancer patients
HK1262015A1 (en) Methods for predicting drug responsiveness in cancer patients
US20190345564A1 (en) Early diagnosis method and kit for breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190226

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190912